Crohn's disease
Conditions
Interventions
Experimental group:The treatment regimen for the experimental group was novel biologics plus total enteral nutrition (EEN) orally.
control group:The control group was treated with a novel biologic agent (ulinumab or Vederizumab)
Sponsors
Zhangzhou Affiliated Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Confirmed Crohn's disease (CD) according to international diagnostic standards 2. Age 18-65 years old 3. CDAI score =150 at the time of enrollment, that is, they were in the active stage of disease 4.CD lesions involved the small intestine (at least the ileum) 5. No adjustment of CD medication regimen during treatment 6. The patient's clinical history and follow-up data were complete
Exclusion criteria
Exclusion criteria: Patients diagnosed with short bowel syndrome or with ileostomy or colostomy 2. There are EN contraindications, such as active gastrointestinal hemorrhage and intestinal obstruction 3. Patients who have used biologics within 60 days prior to enrollment or within 5 drug half-lives, whichever is longer 4. Patients with simple colon type CD 5. Patients with metabolic diseases, such as diabetes, hyperthyroidism, etc 6. Pregnant and nursing patients 7. Patients with serious primary diseases such as cardiovascular, liver, kidney and hematopoietic system, mental patients and serious diseases affecting their quality of life 8. Patients with severe active infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Induced remission rate;Nutritional index;Quality of life score; | — |
Countries
China
Contacts
Public ContactLin Han
Zhangzhou Affiliated Hospital of Fujian Medical University
Outcome results
None listed